BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schoennemann KR, Bjerregaard JK, Hansen TP, De Stricker K, Gjerstorff MF, Jensen HA, Vestermark LW, Pfeiffer P. Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum. Gastric Cancer. 2011;14:219-225. [PMID: 21409520 DOI: 10.1007/s10120-011-0031-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Bailey CH, Jameson G, Sima C, Fleck S, White E, Von Hoff DD, Weiss GJ. Progression-free Survival Decreases with Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials. J Cancer 2012;3:7-13. [PMID: 22211140 DOI: 10.7150/jca.3.7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
2 Thallinger CM, Raderer M, Hejna M. Esophageal cancer: a critical evaluation of systemic second-line therapy. J Clin Oncol. 2011;29:4709-4714. [PMID: 22067408 DOI: 10.1200/jco.2011.36.7599] [Cited by in Crossref: 76] [Cited by in F6Publishing: 38] [Article Influence: 6.9] [Reference Citation Analysis]
3 Ba M, Long H, Zhang X, Gong Y, Tang Y, Wu Y, Yu F, Cui S. Laparoscopic Hyperthermic Intraperitoneal Perfusion Chemotherapy for Patients with Malignant Ascites Secondary to Unresectable Gastric Cancer. Journal of Laparoendoscopic & Advanced Surgical Techniques 2016;26:32-9. [DOI: 10.1089/lap.2015.0266] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
4 Wiedmann MW, Mössner J. New and emerging combination therapies for esophageal cancer. Cancer Manag Res 2013;5:133-46. [PMID: 23869177 DOI: 10.2147/CMAR.S32199] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
5 Wang X, Wang X, Huang J. Irinotecan plus fluorouracil-based regimen as second or third-line chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma. Thorac Cancer 2016;7:246-50. [PMID: 27042229 DOI: 10.1111/1759-7714.12323] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
6 Pasini F, Fraccon AP, Modena Y, Bencivenga M, Giacopuzzi S, La Russa F, Gusella M, de Manzoni G. Targeted therapies for advanced and metastatic adenocarcinoma of the gastroesophageal junction: is there something new? Gastric Cancer 2017;20:31-42. [PMID: 27568322 DOI: 10.1007/s10120-016-0626-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
7 Lee SY, Oh SC. Changing strategies for target therapy in gastric cancer. World J Gastroenterol 2016; 22(3): 1179-1189 [PMID: 26811656 DOI: 10.3748/wjg.v22.i3.1179] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
8 Ba MC, Long H, Zhang XL, Gong YF, Tang YQ, Wu YB, Yu FH, Cui SZ. Laparoscopic Hyperthermic Intraperitoneal Perfusion Chemotherapy for Patients With Malignant Ascites Secondary to Unresectable Gastric Cancer. Surg Laparosc Endosc Percutan Tech 2020;30:55-61. [PMID: 32004214 DOI: 10.1097/SLE.0000000000000380] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Roberto M, Romiti A, Onesti CE, Zullo A, Falcone R, Marchetti P. Evolving treatments for advanced gastric cancer: appraisal of the survival trend. Expert Rev Anticancer Ther 2016;16:717-29. [PMID: 27137418 DOI: 10.1080/14737140.2016.1184979] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
10 Schønnemann KR, Yilmaz M, Bjerregaard JK, Nielsen KM, Pfeiffer P. Phase II study of biweekly cetuximab in combination with irinotecan as second-line treatment in patients with platinum-resistant gastro-oesophageal cancer. Eur J Cancer. 2012;48:510-517. [PMID: 22244801 DOI: 10.1016/j.ejca.2011.12.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
11 Delaunoit T. Latest developments and emerging treatment options in the management of stomach cancer. Cancer Manag Res 2011;3:257-66. [PMID: 21792334 DOI: 10.2147/CMR.S12713] [Cited by in Crossref: 1] [Cited by in F6Publishing: 12] [Article Influence: 0.1] [Reference Citation Analysis]
12 Liu L, Wu N, Li J. Novel targeted agents for gastric cancer. J Hematol Oncol. 2012;5:31. [PMID: 22709792 DOI: 10.1186/1756-8722-5-31] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
13 De Vita F, Giuliani F, Silvestris N, Rossetti S, Pizzolorusso A, Santabarbara G, Galizia G, Colucci G, Ciardiello F, Orditura M. Current status of targeted therapies in advanced gastric cancer. Expert Opin Ther Targets. 2012;16 Suppl 2:S29-S34. [PMID: 22443228 DOI: 10.1517/14728222.2011.652616] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
14 Burtness B, Ilson D, Iqbal S. New Directions in Perioperative Management of Locally Advanced Esophagogastric Cancer. American Society of Clinical Oncology Educational Book 2014. [DOI: 10.14694/edbook_am.2014.34.e172] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]